Latest Share Options News

Neurotech International reported a 23% revenue drop and a doubling of its net loss to $10.6 million for FY25, driven by reduced R&D grants and high development costs. Despite financial pressures, the company marked significant clinical and regulatory progress for its NTI164 cannabinoid therapy.

Cann Group Limited reported a significant 56% reduction in net loss for FY25, driven by cost cuts and strong growth in dried flower sales, even as revenue declined due to shifting product preferences. The company faces going concern challenges but is actively pursuing debt refinancing and operational improvements.

Adslot Ltd reported a 34% drop in revenue to $5.77 million for FY25 but significantly reduced its net loss by 65% to $3.7 million, driven by cost cuts and strategic partnerships. The company is focused on growing its Trading Technology segment despite ongoing market challenges.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

FlexiRoam Limited reported an 8.6% revenue decline for FY25 but achieved a remarkable turnaround in the second half, posting positive EBITDA and net profit after a CEO-led operational reset.

Murray Cod Australia Limited has reported a remarkable turnaround with a $8.56 million profit for FY25, driven by expanded production capacity and growing export markets. The company’s strategic focus on domestic strength and sustainable growth underpins its rising global profile.

PARKD Limited reported a remarkable 218% increase in revenue to $11.83 million for FY25, driven by key construction projects and new licensing agreements. The company narrowed its loss by 74%, signaling progress in commercialising its modular construction technology.

PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.

Echelon Resources Limited reported a robust financial year ending June 2025, driven by strategic asset acquisitions and strong commodity prices, delivering a 34% revenue increase and a near 20-fold jump in net profit after tax.

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

Cynata Therapeutics reported a $9.39 million net loss for FY2025, slightly improved from the prior year, while progressing multiple clinical trials with key results expected in 2026. The company maintains a solid cash position and funding runway through mid-2026, supported by recent capital raises and an equity subscription agreement.

Aurora Labs reported a 34% increase in loss after tax to $3.75 million for FY2025, alongside a 327% surge in revenue driven by defence contracts and 3D printing services. The company is progressing its micro gas turbine propulsion systems and pursuing aerospace certification to expand its market footprint.